查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840883

重症肌无力治疗市场按治疗层级、给药途径、通路和最终用户划分 - 全球预测 2025-2032

Myasthenia Gravis Treatment Market by Treatment Class, Administration Route, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，重症肌无力治疗市场规模将成长 31 亿美元，复合年增长率为 5.62%。

关键市场统计数据
基准年 2024 20亿美元
预计年份：2025年 21.1亿美元
预测年份 2032 31亿美元
复合年增长率 (%) 5.62%

一个涵盖临床选择、治疗路径和营运压力的综合框架，定义了重症肌无力患者的当代护理

重症肌无力的治疗模式复杂，临床表现多样，治疗方法不断发展，监管环境也十分复杂。患者和临床医生必须在众多治疗方案中做出选择，从乙酰胆碱酯酶抑制剂等对症治疗，到糖皮质激素、非类固醇类抗发炎药、静脉注射免疫球蛋白、血浆置换，以及不断扩展的生物目标等免疫调节疗法。本报告整合了临床、商业和供应链等多个视角，揭示了治疗策略如何朝着精准治疗的方向发展，旨在提高疾病的长期控制率，同时降低累积毒性。

随着诊断准确性的提高和治疗模式转向针对特定患者群体的早期强化治疗转变，相关人员在治疗顺序、给药物流和支付方参与方面面临新的决策。现今的治疗生态系统既包括长期使用的口服药物，也包括高成本的静脉注射和皮下注射生物製药，这需要协调的治疗路径、输注能力管理和替代分销方案。因此，本文将探讨常见的临床实践、应用动态以及对医疗服务提供者、生产商和经销商的营运影响。

本导言着重阐述可操作的见解，揭示产品选择的临床驱动因素、限制产品可及性的营运瓶颈，以及影响产品推广时机的监管和报销动态。后续章节将围绕这些主题展开，重点在于阐述投资、伙伴关係和流程再造如何能显着改善病患预后和提升系统效率。

标靶免疫疗法、分散式给药和新兴证据的进展如何重塑临床实践中的治疗选择和护理模式

重症肌无力的治疗模式正在经历变革性变化，这主要得益于标靶免疫学创新、便捷给药方式以及不断发展的医疗服务模式。标靶补体抑制剂和FcRn定向药物的出现，拓展了治疗手段，使其不再局限于广谱免疫抑制，使临床医生能够根据免疫抗原性机制和患者表型製定个性化的治疗方案。同时，生物相似药和新一代抗体计画的成熟也开始影响筹资策略和治疗顺序，迫使支付者和医疗服务提供者重新评估药物製剂和阶梯治疗方案。

同时，向门诊和居家输液治疗的转变正在重塑患者接受治疗的场所，减少了对医院输液中心的依赖，并推动了对皮下和居家输液管理方面的培训、通路和安全通讯协定的投资。随着医疗服务从集中式门诊服务转向居家输液，这种去中心化趋势影响了药品分销管道和药房伙伴关係。

监管路径和真实世界证据倡议也是推动这一转变的关键因素。核准后的数据生成和适应症扩展正在使监管机构的预期与支付方的需求保持一致，从而形成一个反馈循环，加速基于循证医学的标靶治疗的应用。总而言之，这些动态正在缩短临床差异化产品的推广应用时间，同时提升整合商业化策略的重要性，这些策略应涵盖临床教育、供应弹性以及与支付方的协调。

评估2025年关税调整如何影响重症肌无力治疗用生物製药的供应链、筹资策略与临床进入动态

2025年实施的关税政策变化所带来的累积影响正波及整个医药供应链，尤其对依赖生物製药（如重症肌无力）影响尤为显着。关税引发的进口成本调整迫使生产商和经销商重新评估其全球采购、製造外包关係以及产能过剩计划，以确保复杂注射和输液产品的持续供应。为此，供应链领导者正在寻求供应商多元化并增加库存缓衝，同时采购团队也在加速推进区域化策略，以降低单一产地生产的风险。

这些政策转变也促使人们更加关注分销经济学。医院系统和专科药房不得不调整其合约条款以适应不断变化的土地成本，一些医疗机构也重新协商了服务协议，以确保能够持续为重症患者提供服务。支付者和机构采购者也加强了围绕价格和价值的讨论，强调医疗总成本和实际疗效是谈判的关键因素。

在临床层面，关税主导的环境促使相关人员更加关注优化治疗方案，给药途径和给药频率有时会影响维持病人用药可及性和控制病人自付费用的决策。监管和贸易政策的不确定性进一步凸显了情境规划、可扩展生产和有针对性的临床传播策略的重要性，这些策略旨在让临床医生和患者确信，儘管面临全球贸易逆风，治疗的连续性仍然是首要任务。

透过对治疗层级、给药途径、管道和最终用户背景进行详细的細項分析，揭示可操作的临床和物流决策点。

细分市场层面的动态变化揭示了在设计临床路径和商业策略时，治疗、物流和通路特定因素如何相互交织。基于治疗层级，我们涵盖了乙酰胆碱酯酶抑制剂、免疫抑制剂、静脉注射免疫球蛋白、单株抗体和血浆置换。免疫抑制剂进一步分为糖皮质激素和非类固醇免疫抑制剂，后者分别针对Azathioprine、Cyclosporine和RituximabMycophenolate Mofetil进行单独分析。单株抗体则专门针对Eculizumab、Ravulizumab和利妥昔单抗进行分析。这种分类有助于明确临床决策标准：症状治疗与免疫调节治疗、长期维持治疗与急性抢救治疗，以及机制特异性标靶治疗与广谱免疫抑制。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将新生儿Fc受体抑制剂（如efgartigimod）整合到重症肌无力全身型患者的早期治疗流程中
  • 由于在难治性全身性重症肌无力患者中取得了积极的临床试验结果，对补体 C5 抑制剂的需求正在增加。
  • 新兴的双特异性T细胞衔接器疗法可为乙酰胆碱受体阳性重症肌无力患者提供标靶免疫调节
  • 开发皮下注射免疫球蛋白製剂，以提高慢性重症肌无力患者的依从性和生活质量
  • 扩大远端医疗监测项目，以促进重症肌无力患者的远距症状追踪和个人化治疗调整
  • 产业加大对新型生物标记的投资，以用于重症肌无力的准确严重程度评估和个人化治疗选择
  • 生物类似免疫球蛋白产品的激增对品牌静脉注射疗法构成了挑战，并影响了市场定价趋势。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 重症肌无力药物市场（依治疗层级划分）

  • 乙酰胆碱酯酶抑制剂
  • 免疫抑制剂
    • 皮质类固醇
    • 非类固醇免疫抑制剂
      • Azathioprine
      • Cyclosporine
      • Mycophenolate Mofetil
  • 静脉注射免疫球蛋白
  • 单株抗体
    • Eculizumab
    • Ravulizumab
    • Rituximab
  • 血浆置换

9. 重症肌无力治疗市场（依给药途径划分）

  • 静脉
  • 口服
  • 皮下

第十章：重症肌无力药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章：重症肌无力治疗市场（依最终使用者划分）

  • 诊所
  • 居家照护
  • 医院

第十二章：重症肌无力药物市场区域分析

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：重症肌无力药物市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：各国重症肌无力药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Alexion Pharmaceuticals, Inc.
    • argenx SE
    • UCB SA
    • Takeda Pharmaceutical Company Limited
    • Sanofi SA
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • CSL Limited
    • Roche Holding AG
Product Code: MRR-0A609A26A9B8

The Myasthenia Gravis Treatment Market is projected to grow by USD 3.10 billion at a CAGR of 5.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.00 billion
Estimated Year [2025] USD 2.11 billion
Forecast Year [2032] USD 3.10 billion
CAGR (%) 5.62%

A comprehensive framing of clinical choices, therapeutic pathways, and operational pressures that define contemporary care for patients living with myasthenia gravis

Myasthenia gravis presents a complex therapeutic landscape shaped by heterogeneous disease presentations, evolving treatment modalities, and an increasingly sophisticated regulatory environment. Patients and clinicians navigate choices that range from symptomatic management with acetylcholinesterase inhibitors to immune modulation through corticosteroids, nonsteroidal agents, intravenous immunoglobulin, plasma exchange, and an expanding array of targeted biologics. This report synthesizes clinical, commercial, and supply-chain perspectives to clarify how therapeutic strategies are converging toward precision approaches that aim to improve durable disease control while reducing cumulative toxicity.

As diagnostic accuracy improves and treatment paradigms shift toward earlier intensification for select patient segments, stakeholders face new decisions about sequencing, administration logistics, and payer engagement. The therapeutic ecosystem now includes long-established oral agents alongside high-cost intravenous and subcutaneous biologics, which together demand coordinated care pathways, infusion capacity management, and alternative distribution solutions. Accordingly, the introduction frames prevailing clinical practices, adoption dynamics, and the operational implications for providers, manufacturers, and distributors.

Throughout this introduction, emphasis remains on actionable insight: identifying the clinical drivers of product selection, the operational bottlenecks that constrain access, and the regulatory and reimbursement dynamics that shape adoption timing. The subsequent sections build on these themes to reveal where investment, partnership, and process redesign can yield measurable improvements in patient outcomes and system efficiency.

How advances in targeted immunotherapies, decentralized administration, and evidence generation are reshaping treatment choice and care delivery across clinical settings

The therapeutic landscape for myasthenia gravis is undergoing transformative shifts driven by innovations in targeted immunology, simplified administration modalities, and evolving care delivery models. Targeted complement inhibitors and FcRn-directed agents have expanded the armamentarium beyond broad immunosuppression, enabling clinicians to tailor interventions by immunopathogenic mechanism and patient phenotype. At the same time, maturation of biosimilar and next-generation antibody programs has started to influence procurement strategies and treatment sequencing, prompting payers and providers to re-evaluate formulary placement and step therapy paradigms.

Concurrently, a pivot to outpatient and home-based infusion care is reshaping where patients receive treatment, reducing reliance on hospital-based infusion centers and prompting investment in training, remote monitoring, and safety protocols for subcutaneous and home infusion administration. This decentralization has implications for distribution pathways and pharmacy partnerships as care shifts away from centralized ambulatory services.

Regulatory pathways and real-world evidence initiatives are also key levers in this transformation. Post-authorization data generation and adaptive label expansions are aligning regulatory expectations with payer requirements, creating a feedback loop that accelerates evidence-based adoption for targeted therapies. Taken together, these dynamics are compressing time-to-adoption for clinically differentiated products while heightening the importance of integrated commercialization strategies that address clinical education, supply resilience, and payer alignment.

Assessing how 2025 tariff shifts have pressured biologic supply chains, procurement strategies, and clinical access dynamics for therapies used in myasthenia gravis

The cumulative impact of tariff policy changes implemented in 2025 has reverberated across pharmaceutical supply chains, with particular consequences for biologic-dependent therapeutic areas such as myasthenia gravis. Tariff-induced adjustments to import costs have pressured manufacturers and distributors to reassess global sourcing, contract manufacturing relationships, and redundant capacity planning to preserve continuity of supply for complex injectables and intravenous products. In response, supply chain leaders have increased vendor diversification and invested in inventory buffers, while procurement teams have accelerated regionalization strategies to reduce exposure to single-origin manufacturing risks.

These policy shifts have also prompted greater scrutiny of distribution economics. Hospital systems and specialty pharmacies have had to adapt contracting practices to accommodate altered landed costs, and some providers have renegotiated service agreements to maintain stable access for high-acuity patients. Payers and institutional buyers intensified price and value discussions, emphasizing total cost of care and real-world effectiveness as negotiation anchors.

Clinically, the tariff-driven environment intensified stakeholder focus on treatment choice optimization, where administration route and frequency sometimes influenced decisions designed to preserve access and manage patient out-of-pocket exposure. Regulatory and trade policy uncertainty has further underscored the importance of scenario planning, expandable manufacturing, and targeted clinical communication strategies to reassure clinicians and patients that therapeutic continuity remains a priority despite global trade headwinds.

Detailed segmentation analysis connecting therapeutic classes, administration routes, channels, and end-user contexts to reveal actionable clinical and logistical decision points

Segment-level dynamics illuminate how therapeutic, logistical, and channel-specific considerations intersect when designing clinical pathways and commercial strategies. Based on Treatment Class, the landscape encompasses acetylcholinesterase inhibitors, immunosuppressants, intravenous immunoglobulin, monoclonal antibodies, and plasma exchange, with immunosuppressants further disaggregated into corticosteroids and nonsteroidal immunosuppressants, and the latter examined across azathioprine, cyclosporine, and mycophenolate mofetil, while monoclonal antibodies are analyzed with specific attention to eculizumab, ravulizumab, and rituximab. This taxonomy clarifies clinical decision nodes: symptomatic control versus immune modulation, long-term maintenance versus acute rescue, and mechanism-specific targeting versus broad immune suppression.

Based on Administration Route, therapies are considered across intravenous, oral, and subcutaneous modalities, highlighting trade-offs in patient convenience, infusion resource needs, and monitoring intensity. Based on Distribution Channel, the analysis evaluates hospital pharmacies, online pharmacies, and retail pharmacies to reveal how procurement practices, reimbursement pathways, and controlled-drug handling requirements shape product availability. Based on End User, the report separates clinics, home care, and hospitals to capture differences in staffing, infrastructure, and care coordination needs that influence where therapies are initiated, continued, or transitioned.

By integrating these segmentation lenses, stakeholders can identify which therapeutic classes align with existing care infrastructure, where investments in training or infusion capacity will unlock access, and how distribution partnerships can be structured to support diverse administration settings.

How regional regulatory, procurement, and care-delivery differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access and adoption dynamics

Regional dynamics materially influence clinical practice patterns, distribution strategies, and regulatory-compliance priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated centers of excellence and established specialty pharmacy networks support adoption of high-cost biologics, while payer-driven utilization management and reimbursement negotiations shape access pathways and require robust real-world evidence to secure favorable positioning. This region emphasizes integration between tertiary care centers and outpatient infusion capabilities, facilitating earlier use of targeted therapies for well-characterized patient cohorts.

Across Europe, Middle East & Africa, fragmented regulatory and reimbursement environments produce heterogenous adoption curves; centralized health technology assessment processes, country-level formulary decisions, and variable infusion capacity drive differentiated clinical protocols. Stakeholders in this region often prioritize cost-effectiveness analyses and regional manufacturing partnerships to mitigate supply chain exposure and align with public procurement frameworks.

In the Asia-Pacific region, capacity expansion for biologics and rising investment in specialty care infrastructure coexist with diverse regulatory pathways and price sensitivity. Local manufacturing and biosimilar uptake are prominent strategies to increase access, while growing clinical trial activity and real-world data collection create opportunities for evidence generation tailored to regional patient populations. Across all regions, alignment between supply-chain resilience, payer engagement, and clinician education remains central to sustaining access to advanced therapies.

Competitive positioning and partnership playbooks that combine clinical differentiation, distribution capability, and service models to sustain adoption and supply resilience

Competitive dynamics reflect a combination of incumbent biologic manufacturers, emerging targeted therapy developers, and service providers focused on distribution and infusion management. Established companies with complement inhibitors and legacy monoclonal antibody portfolios continue to leverage integrated commercial teams, clinician relationships, and durable manufacturing footprints to support product availability and clinical adoption. Simultaneously, newer entrants that advance FcRn modulation and next-generation antibody formats emphasize differentiated clinical data, dosing convenience, and value communication to payers and providers.

Service-oriented organizations and specialty pharmacies have become critical partners in enabling home and outpatient administration, offering training, remote monitoring, and patient support programs that reduce the burden on hospital infusion centers. Contract manufacturing organizations and regional fill-finish sites play an increasingly strategic role in mitigating trade-related disruptions by offering localized capacity and flexible production scheduling.

Across the competitive set, companies that align clinical differentiation with pragmatic delivery solutions-such as lower-frequency dosing, simplified storage needs, or subcutaneous formulations-are better positioned to influence treatment algorithms and secure inclusion in institution-level formularies. Successful commercial strategies increasingly combine robust post-authorization evidence plans with targeted investments in channel partnerships that ensure both clinical uptake and operational sustainability.

Actionable steps for manufacturers and providers to align evidence generation, supply redundancy, channel integration, and value-based engagement for durable access

Industry leaders can translate insight into operational advantage by coordinating clinical evidence programs, supply resilience initiatives, and stakeholder engagement tactics. First, align clinical-development timelines with pragmatic evidence generation: complement controlled trial data with real-world studies that address payer and clinician questions about durability, safety in diverse populations, and comparative effectiveness across existing standards of care, thereby strengthening value propositions used in reimbursement discussions.

Second, invest in supply-chain redundancy and regionally distributed manufacturing or fill-finish agreements to reduce exposure to trade policy fluctuations and to support predictable delivery for high-acuity therapies. This should be paired with flexible contracting that accounts for administration-site shifts from hospitals to home or clinic settings. Third, design commercialization approaches that prioritize channel integration: partner with hospital pharmacies, specialty and online pharmacy providers, and home-infusion service vendors to create seamless patient journeys that reduce administrative burden and improve adherence.

Finally, adopt proactive payer engagement and pricing strategies that emphasize total cost of care and patient-centric outcomes, and prepare tailored economic models that reflect real-world utilization patterns. By synchronizing clinical, operational, and commercial levers, leaders can improve access, reduce treatment disruptions, and create defensible positioning in an increasingly competitive therapeutic arena.

A rigorous mixed-methods approach combining clinician interviews, operational site assessments, and evidence synthesis to ensure actionable and verifiable conclusions

This analysis synthesizes primary and secondary inputs to ensure conclusions are grounded in clinical practice and operational reality. Primary research included structured interviews with neurologists, infusion center directors, specialty pharmacy leaders, regulatory experts, and payer representatives to capture frontline perspectives on treatment selection, administration logistics, and reimbursement hurdles. These conversations were complemented by site visits and protocol reviews that clarified the operational implications of shifting care from inpatient settings to outpatient and home-based models.

Secondary research drew on peer-reviewed literature, regulatory filings, clinical trial registries, and public policy documents to map therapeutic mechanisms, approved indications, and label requirements. Supply-chain and trade policy assessments used customs guidance and industry analyses to evaluate tariff impacts and sourcing strategies. Data triangulation combined qualitative insights with operational metrics to validate hypotheses about distribution channel performance, staffing constraints for infusion services, and barriers to home-based administration.

Limitations include variability in regional practice patterns and the evolving evidence base for newer agents, which necessitates ongoing monitoring of post-authorization data and payer decisions. To mitigate these constraints, the methodology emphasizes iterative stakeholder engagement and recommends periodic updates to reflect emerging clinical data, regulatory actions, and trade-policy developments.

Concluding synthesis that ties therapeutic innovation to practical execution imperatives required for sustained patient access and system-level value

The landscape of treatment for myasthenia gravis is defined by a convergence of clinical innovation, evolving delivery models, and logistical complexity. Targeted biologics and novel immunomodulatory strategies offer the potential for more precise disease control, yet their value is realized only when paired with robust distribution strategies, adaptable infusion capacity, and payer-aligned evidence packages. Trade policy dynamics and regional regulatory heterogeneity add further layers of operational complexity that stakeholders must actively manage.

Ultimately, success in this therapeutic area depends on integrating clinical differentiation with practical execution: aligning dosing and administration characteristics to provider workflows, ensuring supply-chain redundancy to safeguard continuity, and generating the real-world evidence that resonates with payers and clinicians. Cross-functional collaboration-spanning clinical development, supply chain, market access, and channel partners-will be essential to translate therapeutic promise into sustained patient benefit.

As care models continue to decentralize and as new mechanisms of action emerge, stakeholders that anticipate operational challenges and structure flexible, evidence-driven engagement strategies will be best positioned to expand access while maintaining programmatic and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of neonatal Fc receptor inhibitors like efgartigimod into early-line treatment algorithms for generalized myasthenia gravis patients
  • 5.2. Rising demand for complement C5 inhibitors driven by favorable clinical trial results in refractory generalized myasthenia gravis populations
  • 5.3. Emergence of bispecific T cell engager therapies offering targeted immunomodulation in acetylcholine receptor positive myasthenia gravis
  • 5.4. Development of subcutaneous immunoglobulin formulations enhancing patient adherence and quality of life in chronic myasthenia gravis management
  • 5.5. Expansion of telehealth monitoring programs to facilitate remote symptom tracking and individualized treatment adjustments in MG patients
  • 5.6. Increasing industry investment in novel biomarkers for precise disease severity assessment and personalized therapy selection in myasthenia gravis
  • 5.7. Growing proliferation of biosimilar immunoglobulin products challenging branded intravenous therapies and influencing market pricing dynamics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Myasthenia Gravis Treatment Market, by Treatment Class

  • 8.1. Acetylcholinesterase Inhibitors
  • 8.2. Immunosuppressants
    • 8.2.1. Corticosteroids
    • 8.2.2. Nonsteroidal Immunosuppressants
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Cyclosporine
      • 8.2.2.3. Mycophenolate Mofetil
  • 8.3. Intravenous Immunoglobulin
  • 8.4. Monoclonal Antibodies
    • 8.4.1. Eculizumab
    • 8.4.2. Ravulizumab
    • 8.4.3. Rituximab
  • 8.5. Plasma Exchange

9. Myasthenia Gravis Treatment Market, by Administration Route

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Myasthenia Gravis Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Myasthenia Gravis Treatment Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Myasthenia Gravis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Myasthenia Gravis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Myasthenia Gravis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Alexion Pharmaceuticals, Inc.
    • 15.3.2. argenx SE
    • 15.3.3. UCB S.A.
    • 15.3.4. Takeda Pharmaceutical Company Limited
    • 15.3.5. Sanofi S.A.
    • 15.3.6. Johnson & Johnson
    • 15.3.7. Pfizer Inc.
    • 15.3.8. Novartis AG
    • 15.3.9. CSL Limited
    • 15.3.10. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SI